Cargando…

Targeting BET Proteins With a PROTAC Molecule Elicits Potent Anticancer Activity in HCC Cells

Background and Aim: Bromodomain and extraterminal domain (BET) family proteins are epigenetic regulators involved in human malignances. Targeting BET proteins for degradation using proteolysis-targeting chimera (PROTAC) recently has drawn increasing attention in the field of cancer therapeutics. BET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Huapeng, Li, Gongquan, Zhang, Yi, Shi, Jihua, Yan, Bing, Tang, Hongwei, Chen, Sanyang, Zhang, Jiakai, Wen, Peihao, Wang, Zhihui, Pang, Chun, Li, Jie, Guo, Wenzhi, Zhang, Shuijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971110/ https://www.ncbi.nlm.nih.gov/pubmed/31993368 http://dx.doi.org/10.3389/fonc.2019.01471

Ejemplares similares

PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
por: Shi, Chengcheng, et al.
Publicado: (2019)

Microarray Analysis For Expression Profiles of lncRNAs and circRNAs in Rat Liver after Brain-Dead Donor Liver Transplantation
por: Chen, Sanyang, et al.
Publicado: (2019)

Sirt6 opposes glycochenodeoxycholate-induced apoptosis of biliary epithelial cells through the AMPK/PGC-1α pathway
por: Li, Jiye, et al.
Publicado: (2020)

Polymorphisms and expression pattern of circular RNA circ-ITCH contributes to the carcinogenesis of hepatocellular carcinoma
por: Guo, Wenzhi, et al.
Publicado: (2017)

Caspase-1 Inhibitor Reduces Pyroptosis Induced by Brain Death in Kidney
por: Liu, Weifeng, et al.
Publicado: (2021)

Mitogen activated protein kinase phosphatase 5 alleviates liver ischemia–reperfusion injury by inhibiting TAK1/JNK/p38 pathway
por: Yu, Qiwen, et al.
Publicado: (2023)

miR-140-5p alleviates mouse liver ischemia/reperfusion injury by targeting CAPN1
por: Yu, Qiwen, et al.
Publicado: (2021)

The reasonable therapeutic modality for biliary duct-to-duct anastomotic stricture after liver transplantation: ERCP or PTC?
por: Bowen, Hu, et al.
Publicado: (2022)

Leptin concentration and risk of coronary heart disease and stroke: A systematic review and meta-analysis
por: Yang, Han, et al.
Publicado: (2017)

Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma
por: Hu, Bowen, et al.
Publicado: (2022)

Molecular characteristics of novel immune subtypes of HCC based on lncRNAs related to immune disorders
por: Zhang, Qiyao, et al.
Publicado: (2022)

Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway
por: Liu, Xudong, et al.
Publicado: (2022)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Dopamine and dopamine receptor D1 as a novel favourable biomarker for hepatocellular carcinoma
por: Wang, Zhihui, et al.
Publicado: (2021)

Identification of Context-Specific Fitness Genes Associated With Metabolic Rearrangements for Prognosis and Potential Treatment Targets for Liver Cancer
por: Yu, Shizhe, et al.
Publicado: (2022)

CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma
por: Liu, Long, et al.
Publicado: (2022)

Single nucleotide polymorphisms in interleukin-6 attenuates hepatocytes injury in hypoxia/re-oxygenation via STAT3 signal pathway mediated autophagy
por: Tang, Hongwei, et al.
Publicado: (2021)

Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs
por: Qin, Qiaohua, et al.
Publicado: (2022)

Smac Mimetic SM-164 Potentiates APO2L/TRAIL- and Doxorubicin-Mediated Anticancer Activity in Human Hepatocellular Carcinoma Cells
por: Zhang, Shuijun, et al.
Publicado: (2012)

The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage
por: Zhu, Xingfei, et al.
Publicado: (2023)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019)

ACADL Functions as a Tumor Suppressor in Hepatocellular Carcinoma Metastasis by Inhibiting Matrix Metalloproteinase 14
por: Guo, Danfeng, et al.
Publicado: (2022)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Tumor PHD2 Expression Is Correlated With Clinical Features and Prognosis of Patients With HCC Receiving Liver Resection
por: Zhen, Li, et al.
Publicado: (2014)

Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs
por: Muddassir, Mohd., et al.
Publicado: (2020)

FXR1 promotes proliferation, invasion and migration of hepatocellular carcinoma in vitro and in vivo
por: Zhao, Kun, et al.
Publicado: (2022)

A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity
por: Khan, Sajid, et al.
Publicado: (2019)

The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs
por: Liu, Pei Y., et al.
Publicado: (2016)

Developing potent PROTACs tools for selective degradation of HDAC6 protein
por: An, Zixuan, et al.
Publicado: (2019)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
por: Li, Pengyun, et al.
Publicado: (2023)

Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
por: Yang, Jianzhang, et al.
Publicado: (2022)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

Rational Design and Synthesis of HSF1-PROTACs for Anticancer Drug Development
por: Sharma, Chiranjeev, et al.
Publicado: (2022)

A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells
por: Zhang, Kunlong, et al.
Publicado: (2022)

Correction to: Developing potent PROTACs tools for selective degradation of HDAC6 protein
por: An, Zixuan, et al.
Publicado: (2019)

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer
por: Cimas, Francisco J., et al.
Publicado: (2020)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t626sdfc0g2i5oag45nus5u3s0